As a major negative regulator of p53, the MDM2 oncogene plays an important role in carcinogenesis and tumor progression. MDM2 promotes p53 proteasomal degradation and negatively regulates p53 function. The mechanisms by which the MDM2-p53 interaction is regulated are not fully understood, although several MDM2-interacting molecules have recently been identified. To search for novel MDM2-binding partners, we screened a human prostate cDNA library by the yeast two-hybrid assay using full-length MDM2 protein as the bait. Among the candidate proteins, ribosomal protein S7 was identified and confirmed as a novel MDM2-interacting protein.
Introduction
MDM2, an oncogenic cellular E3 ligase of p53, has been implicated in the initiation, progression and resistance to therapy of cancer (Lane and Hall, 1997) . By catalysing the ubiquitination of p53, MDM2 promotes p53 protein degradation and, in turn, MDM2 is transactivated by p53 (Haupt et al., 1997) . Additionally, MDM2 binds to the transcriptional activation domain of p53 and blocks its transactivation activities (Haupt et al., 1997) .
The tumor suppressor p53 has the capacity to induce apoptosis, cell cycle arrest or senescence (Lane, 1992; Levine, 1997) . These functions are critical to the prevention of cell transformation, tumor formation and progression; loss of functional p53 results in malignancy (Attardi and Jacks, 1999; Vogelstein et al., 2000) .
Besides p53, MDM2 binds to a number of proteins with various functions . For example, MDM2 interacts with molecules regulating cell cycle progression, p21 WAF1/CIP1 (Jin et al., 2003; Zhang et al., 2004) and E2F1 (Zhang et al., 2005b) , and modulates their activities. Other MDM2-binding partners, including pRb, MDM4, nucleophosmin, Merlin, estrogen receptor-a and the androgen receptor have also been identified .
As overexpression of MDM2 is seen in many human malignancies (Bond et al., 2004) and is associated with poor prognosis (Poyurovsky and Prives, 2006) , MDM2 has been suggested as a novel target for human cancer therapy (Zhang et al., 2005a) . We have generated second-generation anti-MDM2 antisense oligonucleotides (Zhang et al., 2005a) to target the protein. These antisense inhibitors have antitumor activity and chemosensitization and radiosensitization effects in a variety of tumor models, regardless of their p53 statuses (Wang et al., 2003; Zhang et al., 2003b Zhang et al., , 2005a . Although several binding partners of MDM2 have been discovered, the mechanisms responsible for the p53-independent tumorigenicity of MDM2 are not fully understood.
The present study was designed to search for novel MDM2-binding proteins. We screened the human prostate MATCHMAKER cDNA library using the yeast two-hybrid assay with full-length MDM2 as the bait. Among the potential novel MDM2 interacting partners, S7, a component of the small subunit of ribosomes, was identified, and its interaction with MDM2 was confirmed in vitro and in vivo. We observed that S7 modulates the MDM2-p53 interaction by forming a ternary complex among S7, MDM2 and p53, which leads to the stabilization of p53 protein by inhibiting the activities of MDM2. S7 likely inhibits MDM2-mediated p53 protein degradation through the proteasome, and may also be associated with 'ribosomal stress,' a process that couples ribosome biogenesis to cell cycle arrest or cell death . In fact, the S7-MDM2 interaction resulted in increases in apoptosis and decreases in proliferation in cancer cells. These observations identify an additional regulatory factor for the MDM2-p53 interaction and provide a novel mechanism associated with 'ribosomal stress'.
Results

S7 binds to MDM2 protein
In our previous preclinical studies, we have demonstrated that MDM2 is a valid target for cancer therapy, both dependent and independent of p53 (Zhang et al., 2005a) . However, the mechanisms by which MDM2 exerts its oncogenic effects are not understood entirely. In order to search for novel binding partners of MDM2, we conducted a yeast two-hybrid assay using full-length MDM2 to screen a human prostate MATCHMAKER cDNA library (BD Biosciences, Clontech, Mountain View, CA, USA). Sequence analysis of the candidate MDM2 interacting proteins identified RPL11 (Dai et al., 2006) and RPL23 , which have previously been shown to bind to MDM2. In addition, we identified 11 clones that encode a protein corresponding to full-length human S7.
To confirm the binding between MDM2 and S7, full-length cDNAs of MDM2 and S7 were cloned into pGBKT7 and pGADT7 vectors, respectively, and co-transformed into the yeast host strain AH109. As expected, transformants had the capacity to grow on the yeast Minimal Synthetic Dropout (SD) plate, which lacked adenine (Ade), histidine (His), leucine (Leu) and tryptophan (Trp) (SD/-Ade/-His/-Leu/-Trp) ( Figure 1a ).
In vitro pull-down assays demonstrated direct binding between MDM2 and S7; no co-factors were required. As shown in Figure 1b , GST-MDM2 (b1) or GST-S7 (b2), but not GST, bound to in vitro translated S7 or MDM2, respectively. Consistently, when pCGT-T7-MDM2 and pCMV-Myc-S7 were co-transfected into COS7 cells, sequential immunoprecipitation (IP) using a Myc antibody (Figure 1c1 ) or T7 antibody (Figure 1c2 ) and immunoblotting assay with a T7 antibody or Myc antibody demonstrated binding between MDM2 and S7 ( Figure 1c ). In contrast, there was no MDM2 or S7 detected in Myc or T7 immunoprecipitates of lysates from cells transfected with Myc-S7 alone or T7-MDM2 alone. Under normal physiological conditions, there was an interaction between endogenous MDM2 and S7, as indicated by immunoprecipitation using an MDM2 antibody (H221, Figure 1d1 ) or S7 antibody ( Figure 1d2 ) followed by immunoblotting with an antibody against S7 ( Figure 1d1 ) or MDM2 (SMP14, Figure 1d2 ). These observations indicate that the MDM2 and S7 proteins bind together in vitro and in vivo.
To map the binding domains required for the binding between MDM2 and S7, the yeast two-hybrid method and IP were used. A number of deletion mutants were cloned into pGBKT7 or pCMV-3Tag-2A for expression of MDM2 mutants (Figure 1e1 ), and S7 mutants were cloned into pGADT7 or pEGFP-C1 ( Figure 1f1 ). As demonstrated by the yeast two-hybrid assay, co-transformants of AH109 with full-length S7 and MDM2 1-179 or 299-491 were unable to grow on SD/-Ade/-His/-Leu/-Trp plates (Figure 1e2 ). In contrast, the transformants with other mutants or wild-type MDM2 plus S7 gained the capacity to grow on the SD/-Ade/-His/-Leu/-Trp plates (Figure 1e2 ). This suggests that the binding domain spans amino acids (aa) 180-298 in MDM2. The binding region in MDM2 was then confirmed by the b-galactosidase assay (Figure 1e3 ). Similar procedures indicated that the binding site in the S7 protein is between aa 59 and 134 ( Figure 1f2 , and f3). Although S7 mutants D (aa 59-134) and E (aa 59-194) showed relatively low b-galactosidase activity, the extent (e1) were transformed into AH109. Transformants were plated onto the SD/-Ade/-His/-Leu/-Trp plates, and incubated at 301C for 3-4 days (e2). Colonies growing on the SD/-Leu/-Trp plates were further examined for the activity of b-galactosidase by liquid culture assay using ONPG as the substrate, which confirmed the binding sites in MDM2 (e3). P: positive control. N: negative control. (f) Mapping the MDM2-binding domains in the S7 protein in yeast cells. The binding site in S7 was also determined in yeast as described above. P: positive control. N: negative control. (g) Mapping the binding domains between S7 and MDM2 in COS7 cells. Plasmids expressing full-length GFP-S7 with vectors expressing Myc-tagged wild-type MDM2 or a series of MDM2 mutants were co-transfected into COS7 cells (g1). At 24 h after transfection, the cell lysates were immunoprecipitated with Myc antibody and followed by immunoblotting with GFP antibody (g1). Full-length T7-MDM2 with wildtype or mutant GFP-tagged S7 were overexpressed in COS7 cells, and the binding site in S7 was determined by sequential immunoprecipitation with GFP antibody and immunoblotting with T7 antibody (g2).
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D Chen et al of their activity was at least two times that for the A and F mutants and the negative control ( Figure 1f3) . Further, the A and F transformants were unable to grow on the SD/-Ade/-His/-Leu/-Trp plates (Figure 1f2 ). The low activities for D and E indicate that N-terminal amino acids contribute to the binding between MDM2 and S7.
Further experiments confirmed the binding sites in mammalian cells. When full-length S7 and different mutants of MDM2 were co-transfected into COS7 cells, sequential immunoprecipitation and immunoblotting assays showed that the binding region in MDM2 is between aa 180-298 (Figure 1g1) . Similarly, S7 aa 59-134 are responsible for the S7-MDM2 binding in COS7 cells (Figure 1g2 ). S7 stabilizes p53 protein by modulating the MDM2-p53 interaction MDM2 is the essential cellular ubiquitin E3 ligase for p53 and thus is the major negative regulator of p53 in cells. The identification of multiple regulators of the MDM2-p53 auto-regulation loop has illustrated the important role of the MDM2-p53 interaction in the processes by which cells respond to stress. Moreover, recent studies have shown that constitutive p53 degradation occurs in a strict MDM2-dependent manner (Francoz et al. 2006) . To determine if the S7-MDM2 interaction has effects on the p53 level, Myc-S7 was transiently transfected into U2OS cells ( Figure 2a ). As demonstrated in Figure 2 , overexpression of S7 resulted in a dose-dependent increase in the p53 protein level. 
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The MDM2 level was also elevated, perhaps as a result of disrupting the MDM2-p53 interaction and subsequent elevation of p53 transactivation of the MDM2 gene, similar to that observed following the use of MDM2-p53 interaction inhibitors, like nutlin (Vassilev et al., 2004) .
To determine if S7 acts on p53 at the post-translational level, Myc-S7 was overexpressed in A549 cells, which were then exposed to the protein synthesis inhibitor, cycloheximide (CHX, 10 mg/ml), for different times (Figure 2b1 ). The p53 protein was stabilized in S7 transfected cells relative to cells transfected with the control vector (Figure 2b ). To determine if S7 is essential for p53 regulation in cells, U2OS cells were transfected transiently with S7 siRNA or control siRNA. As shown in Figure 2c , the expression level of S7 was decreased dose-dependently. As a result, the protein expression levels of MDM2 and p53 were decreased.
As a transcription factor, p53 transactivates its target genes to regulate the cellular responses to stress. To determine the consequences of the stabilization of p53 by S7, a p21 luciferase reporter and S7 were co-transfected into U2OS cells. The p21 promoter was activated in S7 transfected cells (Figure 2d ). To verify that the effects resulted from the interaction between MDM2 and S7, the p21 luciferase reporter was transfected into U2OS cells in the presence or absence of ectopically overexpressed MDM2. As expected, p21 luciferase activity was decreased by MDM2, likely as a result of the inhibition of p53 by MDM2. In the presence of S7, however, the inhibition of p21 luciferase activity by MDM2 was partially overcome (Figure 2d) .
As MDM2-mediated p53 ubiquitination is essential for the regulation of p53, and since S7 binds to MDM2, we hypothesized that S7 may abrogate the negative effects of MDM2 on p53. To investigate this hypothesis, Myc-S7 or Myc-p14 Arf , another MDM2 regulator (Pomerantz et al., 1998; Zhang et al., 1998) , was transfected with or without MDM2 into U2OS cells. Transfection with MDM2 reduced the p53 level, an effect that was blocked by co-transfected Myc-S7 or Myc-p14 Arf (Figure 3a) . Further, MDM2-induced p53 ubiquitination, detected by both direct immunoblotting ( Figure 3b1 ) and immunoprecipitation ( Figure  3b2 ), was absent in the cells with co-overexpression of Myc-S7.
The inhibition of MDM2 function may result from modulation of MDM2-p53 binding or from the formation of a ternary complex among MDM2, p53 and S7. To illustrate this point, COS7 cells were transiently transfected with various combinations of plasmids ( Figure 3c1 ). As shown, HA-p53 was detected in GFP-S7 immunoprecipitates of lysates from cells transfected with GFP-S7, T7-MDM2 and HA-p53, but not in cells overexpressed with one or two of these. This indicates the formation of a ternary complex among MDM2, S7 and p53. Further confirmative evidence stems from studies in which U2OS cells were overexpressed with different mutants of S7 plasmids (Figure 3c2 ). Consistently, S7 mutants retaining the capacity for binding to MDM2 (B, C and D) stabilized p53, while those without binding capacity, A and G, did not increase the p53 level in cells (Figure 3c2 ).
Earlier studies have demonstrated that, during 'ribosomal stress,' ribosomal proteins, including L5, L11, and L23, are released and modulate the MDM2-p53 interaction (Lohrum et al., 2003; Zhang et al., 2003a; Bhat et al., 2004; Dai et al., , 2006 . We also observed binding between MDM2 and p53 and between MDM2 and S7 when cells were exposed to low concentrations of actinomycin D (Act D) (5 nM), which disrupts ribosomal biogenesis (Figure 3d ). This likely results from the formation of a ternary complex among S7, MDM2 and p53 following the release of S7 in response to ribosomal stress.
S7 enhances the activities of p53
When activated, the tumor suppressor p53 induces apoptosis, cell cycle arrest or senescence. To investigate the cellular consequences of the MDM2-S7 interaction, we transfected Myc-S7 or S7 siRNA into U2OS cells. Such overexpression or knockdown of S7 resulted in an increase or decrease in apoptosis, respectively (Po0.05) (Figure 4a and e) . In a separate study, overexpressed S7 led to the inhibition of cell proliferation in MCF-7 cells; this effect was partially abrogated by p53 knockdown (Po0.05) (Figure 4b ). To establish that the effects of S7 on apoptosis or proliferation occurred as a result of S7 modulating the MDM2-p53 interaction, stable MCF-7 cell lines with inducible MDM2 overexpression (Figure 4c and d2) and knockdown (Figure 4d1 ), regulated by tetracycline (Tet), were established. The MDM2, p53 and S7 levels in inducible cells after addition of Tet and transfection with S7 are shown in Figure 4c and d1. As expected, the cytotoxicity of S7 was abrogated by inducible overexpression of MDM2 in MCF-7 cells (Figure 4c) . Additionally, the induction of apoptosis by S7 in MCF-7 cells was overcome by MDM2 knockdown (Po0.05) (Figure 4d1 ), or enhanced by MDM2 overexpression (Po0.05) ( Figure  4d2 ) in inducible MCF-7 cell lines in the presence of Tet. Thus, S7 induces apoptosis and inhibits proliferation by modulating MDM2-mediated p53 regulation.
Discussion
In the present study, we have identified S7 as a positive regulator of p53 that functions through modulation of MDM2 activity. Our studies not only identify a novel molecule that regulates the MDM2-p53 loop, but also provide information related to the process of p53 activation in response to cellular stresses.
Several cellular factors that modulate the MDM2-p53 interaction have been identified; these include MDM4 (Xiong et al., 2006) , gankyrin (Higashitsuji et al., 2005) , L11 (Lohrum et al., 2003) 
, p14
Arf , p300 (Grossman et al., 2003) , HAUSP (Li et al., 2002) and YY1 (Sui et al., 2004) . The redundancy in regulators of the MDM2-p53 loop is consistent with the important role that p53 has in protecting the integrity of the genome. The mechanisms S7 stabilizes and activates p53 D Chen et al by which these cofactors are differentially regulated under various cellular conditions are largely unknown. Studies designed to elucidate the mechanisms by which the regulators orchestrate their effects would provide insight into the p53 activation process in the presence of different cellular stresses.
Although the central portion of the MDM2 molecule is important for its activity towards p53, the underlying mechanisms are not clear. Several cofactors, including Rb (Xiao et al., 1995) , p14
Arf , p300, Akt (Zhou et al.,
2001
) and ribosomal proteins L5, L11 and L23 bind to this region. We have identified an additional regulator of MDM2, S7 that binds to this region. As these regulators are involved in different pathways activated by various stimuli, the central region of MDM2 may act as the major sensor of these stimuli and may govern its regulation of p53 in response to different cellular stresses. Although we have observed inhibition of p53 ubiquitination by MDM2 in the presence of S7, the mechanisms are not fully understood. Arf as indicated in the figure. After 24 h, target proteins were detected by specific antibodies. (b) S7 inhibits p53 ubiquitination induced by MDM2. A549 cells were overexpressed with HA-Ub, HAp53, T7-MDM2 and Myc-S7 (b1) or MDM2, Ub-HA and Myc-S7 (b2) in the combinations indicated in the figure. Ubiquitinated p53 was detected either directly by immunoblotting with p53 antibody DO-1 or separated by immunoprecipitation with HA.11 antibody, followed by detection via immunoblotting with p53 antibody DO-1. (c) S7 modulates the MDM2-p53 interaction by forming a ternary complex among S7, MDM2 and p53. (c1) COS7 cells were transfected with combinations of plasmids as indicated in the figure. Cell lysates were immunoprecipitated by GFP antibody followed by immunoblotting with T7, HA, GFP and b-actin antibodies for the immunoprecipitates or the whole cell lysates. (c2) wild-type and mutant S7 were overexpressed in A549 cells, and the target proteins in whole cell lysates were detected by immunoblotting. (d) The S7-MDM2-p53 complex forms after ribosome stress. U2OS cells were exposed to actinomycin D (Act D) (5 nM) for 24 h. MDM2, p53 or S7 proteins in MDM2 immunoprecipitates or in whole cell lysates were separated by SDS-PAGE and detected by immunoblotting.
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We have established that a ternary complex is formed among MDM2, p53 and S7, which may inhibit MDM2 E3 ligase activity. However, the possibility that direct binding between S7 and MDM2 may hinder MDM2's access to p53 cannot be excluded. Further studies employing S7 mutants without binding domain(s) for MDM2 may provide useful information. Another possibility is that S7 recruits other regulators, such as p14
Arf , or proteins of the large subunit of the ribosome. In vitro ubiquitination assays with MDM2 and S7 will help to determine if S7 alone is sufficient for inhibition of MDM2 E3 ligase activity.
Ribosomal integrity is coupled with cell cycle arrest, although the underlying mechanisms are unknown (Du and Stillman, 2002) . In response to cellular stresses, p53 inhibits protein synthesis (Budde and Grummt, 1999) , and p53 is involved in monitoring the disruption of ribosome biogenesis (Pestov et al., 2001) . Several large subunit proteins of the ribosome, L5, L11 and L23, bind to MDM2 thus stabilizing p53 and rescuing its transactivational activities. In this report, we establish that S7, a protein of the small subunit of the ribosome, has the capacity to stabilize p53 by binding to MDM2. This is the first report of a component of the small S7 stabilizes and activates p53 D Chen et al ribosomal subunit mediating the 'ribosomal stress' response. Overall, these studies identify a general pathway leading to p53 activation from perturbation of ribosome biogenesis .
With its p53-dependent and -independent tumorigenic properties, MDM2 has become a novel target for cancer therapy (Zhang et al., 2005a) . Although the p53-independent mechanisms by which it mediates tumorigenesis are unclear, the identification of novel binding partner(s) may be informative. Here, we present evidence that S7 binds to MDM2. It would be desirable to determine if this interaction is important in cancer cells without functional p53. As more than half of human cancers contain nonfunctional p53, studies designed to explore ribosomal stress independent of p53, or in the presence of mutant p53, could have implications for cancer therapy.
Materials and methods
Yeast two-hybrid screening A human prostate MATCHMAKER cDNA library was used for yeast two-hybrid screening. The full-length MDM2 was used as the bait. The pGBKT7-MDM2 and library plasmids were sequentially transformed into yeast host strain AH109. A total of 1 Â 10 7 transformants were plated onto the SD/-Ade/-His/-Leu/-Trp plates, and incubated for 3-4 days at 301C. The DNA of the plasmids of the candidate positive yeast colonies were extracted and co-transformed with the bait plasmid to AH109 for a second round of interaction screening. After verification of true positives, the library plasmids were sequenced and compared to the GenBank database by BLAST.
Plasmids and reagents
The pCMV-S7 and pGEX-5X-1-S7 plasmids were cloned by polymerase chain reaction (PCR) using the following primers: forward, CGGGATCCCGATGTTCAGTTCGAGCGCC and reverse, GTACTCGAGTTACAATTGAAACTCTGGGAA TTCA, and verified by sequencing. The pcGT-T7-MDM2, p53-HA and p21 luciferase vectors were kindly provided by Dr X Chen (UAB). Additional constructs expressing deletions of the MDM2 and S7 proteins were generated by proof-reading PCR. Vectors expressing p14
Arf and HA-Ub were provided by Dr Y Xiong (UNC) and Dr Y Shi (Harvard), respectively. S7 double-stranded siRNA pool, control non-targeting siRNA pool and the transfection reagent DharmaFECT 1 were purchased from Dharmacon (Lafayette, CO, USA). CHX, Actinomycin D and MG132 were from Sigma (St Louis, MO, USA). Rabbit S7 polyclonal antiserum to human RPS7 was generated by ProteinTech (Chicago, IL, USA) using full-length human RPS7 protein as the antigen.
Cell lines MCF-7 and A549 cells were purchased from the ATCC. U2OS cells were kindly provided by Dr X Chen (UAB). MCF-7 cells with stable p53 knockdown were described previously (Li et al., 2005) . All cells were cultured under standard conditions described by the ATCC. MCF-7 stable cell lines with inducible MDM2 knockdown or overexpression were established using the protocol described previously (Liu and Chen, 2006) .
Statistical analysis
The significance of relative cellular apoptotic, proliferation indices and survival rates between various treatments groups were analysed by analysis of variance.
